- Home
- RITM vs LEGN Comparison
RITM vs LEGN Comparison
Compare RITM & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RITM | LEGN |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | 6045 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RITM | LEGN |
|---|---|---|
| Price | $9.03 | $17.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $14.56 | ★ $63.08 |
| AVG Volume (30 Days) | ★ 10.8M | 1.5M |
| Earning Date | 04-24-2026 | 03-10-2026 |
| Dividend Yield | ★ 11.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $46.27 |
| Revenue Next Year | $5.52 | $28.77 |
| P/E Ratio | $10.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.43 | $16.24 |
| 52 Week High | $12.74 | $45.30 |
Technical Indicators
Market Signals| Indicator | RITM | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 30.98 | 38.56 |
| Support Level | N/A | $16.24 |
| Resistance Level | $11.24 | $20.39 |
| Average True Range (ATR) | 0.31 | 0.80 |
| MACD | -0.05 | -0.14 |
| Stochastic Oscillator | 35.63 | 5.42 |
Price Performance
Historical ComparisonAbout RITM Rithm Capital Corp.
Rithm Capital Corp operates as a real estate investment trust that provides capital and services to the real estate and financial services industries. The company aims to generate attractive risk-adjusted returns in all interest-rate environments through a complementary portfolio of investments and operating businesses. Its investment portfolio is composed of mortgage servicing-related assets (full and excess MSRs and servicer advances), residential securities (and associated call rights), loans (including single-family rental), and consumer loans. Its operating segments are Origination and Servicing; Investment Portfolio; Residential Transitional Lending; and Asset Management.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.